Kiniksa Pharmaceuticals International, plc KNSA Gain/Loss on Asset Sales
Gain/Loss on Asset Sales at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's gain/loss on asset sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's gain/loss on asset sales?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported gain/loss on asset sales of $54K in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's gain/loss on asset sales changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's gain/loss on asset sales increased by 640.0% year-over-year, from -$10K to $54K.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's gain/loss on asset sales?
- Over 2 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's gain/loss on asset sales has grown at a 7.9% compound annual growth rate (CAGR), from -$103K to $120K.
- What does gain/loss on asset sales mean?
- Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.